Apellis Pharmaceuticals Inc

NASDAQ:APLS   3:59:58 PM EDT
47.35
-0.25 (-0.52%)
Products

Apellis Announces FDA Acceptance, Priority Review Of NDA For Pegcetacoplan For Treatment Of PNH

Published: 11/16/2020 12:19 GMT
Apellis Pharmaceuticals Inc (APLS) - Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Pnh.
Apellis Pharmaceuticals Inc - PDUFA Target Action Date is May 14, 2021.
Apellis Pharmaceuticals Inc - FDA Has Stated That It is Not Currently Planning to Hold an Advisory Committee Meeting to Discuss Application.